New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors

We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.

This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.

The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.

Latest In Research


Frontline Immunotherapy Trial for EGFR Mutation Positive Patients to Expand Enrollment

Announcing the investigator initiated trial Pembro IST is anticipated to expand enrollment to UCLA satellite sites. Pembrolizumab is an antibody that inhibits the PD-1/PD-L1 immune checkpoint and allows the immune system to des…


Advice From Patients On A Study’s Design Makes For Better Science

Clinical Trials News:  NCI-MATCH trial upends the normal way of classifying cancers for treatment: Instead of categorizing malignancies by the organ where they first appear, this method of sorting focuses on particular mutations in the ge…


Update: CRISPR

Scientists say they’ll someday be able to use CRISPR to fight cancer and maybe even bring animals back from the dead. Read the story:…


Trial for Patients Doing Well on Nivolumab Expands to UCLA

The Checkmate 384 study will is now available at UCLA sites in addition to the sites already open in the TRIO-US network. This study is a dose frequency optimization trial of nivolumab in patients with Stage IIIB or Stage IV squa…


Stand Up To Cancer Ushers In New Approach to Research with Calls by AACR for SU2C Dream Teams on “Interception” of Pancreas and Lung Cancers, Each Funded at $7 Million

Stand Up To Cancer (SU2C) broke new ground today when the American Association for Cancer Research (AACR), its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception…


Advanced NSCLC Patients Live Longer When Treated, but Proportion of Untreated Patients Rising

Patients with advanced non-small cell lung cancer (NSCLC) who receive treatment live longer than those who remain untreated, but the proportion of NSCLC patients with advanced disease who don’t receive treatment has been rising in the Unit…


Multimillion Dollar Grant Awarded from the National Cancer Institute for Translational Research at UCLA and in TRIO-US

The December, 2016 issue of  THORACIC ONCOLOGY TRANSLATIONAL RESEARCH AT UCLA & TRIO-US announces that the National Cancer Institute has awarded funding to study determinants of benefit from PD-1 inhibitors in patients at UCLA (includ…


Personalized Medicine Impacting Study Conduct

“We are moving to an era where we use molecular analysis of patient samples either to enroll people in trials or understand how drugs work or don’t work,” said Ross Levine, M.D., a physician-scientist at the Memorial Slo…


Immunotherapy Agent Improved Quality of Life in Lung Cancer Study

  There was a quality of life improvement for patients with non-small cell lung cancer who were treated with Keytruda compared to those who had standard chemotherapy, according to new data from the trial presented at the IASLC 17th Wo…


Boehringer Ingelheim HCP Survey: Nearly 20% Of Newly Diagnosed Lung Cancer Patients Tested For EGFR Mutations At Risk Of Missing Out On Personalised Treatments For Their Disease

Recent international survey showed high global EGFR testing rates prior to first-line lung cancer therapy but highlighted a shortfall in the number of test results received before deciding on therapy. Nearly one in five patients are at r…

Read More